Chinese company CanSino Biologics is to shortly publish full Phase II results from its COVID-19 vaccine candidate - which it says makes it a leader both in development times and research transparency in the race to develop a vaccine against the coronavirus.
Speaking to Scrip, Pierre Morgon, the company’s senior vice president of international business said the results would be published in...






